Overview

Study of AT-02 in Healthy Volunteers and Subjects With Systemic Amyloidosis

Status:
Not yet recruiting

Trial end date:
2023-09-01

Target enrollment:

Participant gender:

Summary

This is a multicenter, international, two-part, Phase 1 study designed to evaluate the safety, tolerability, and PK of rising single doses of AT-02 in healthy volunteers (HV) and in subjects with systemic amyloidosis (SA).

Phase:

Phase 1

Details

Lead Sponsor:

Attralus, Inc.

Collaborator:

Novotech (Australia) Pty Limited